Hope Dawns for Duchenne Muscular Dystrophy Patients as New Drug Gets FDA Approval

Boy
Duchenne muscular dystrophy commonly affects boys. Wikimedia Commons

The U.S. Food and Drug Administration announced Monday its approval of a drug that treats patients with Duchenne Muscular Dystrophy (DMD).

The drug, Exondys 51 (eteplirsen), is to be used particularly for those with a “confirmed mutation of the dystrophin gene amenable to exon 51 skipping,” a condition said to affect 13 percent of all DMD patients. It is the first drug treatment approved by the FDA to treat the disease.

“Patients with a particular type of Duchenne muscular dystrophy will now have access to an approved treatment for this rare and devastating disease,” Janet Woodcock, director of the agency’s Center for Drug Evaluation and Research, said in a statement.

The agency gave the green light for Exondys 51 despite recommendations from its advisers not to do so.

Although doctors and patients provided testimonies on how the drug was able to allow boys to walk longer, effectively delaying the need for a wheelchair, the agency’s advisers said the drug failed to meet FDA requirements. Additionally, the study presented by the drug’s manufacturer involved only 12 patients.

Woodcock explained drug approval for diseases that affect only a small number of people can be challenging.

“Accelerated approval makes this drug available to patients based on initial data, but we eagerly await learning more about the efficacy of this drug through a confirmatory clinical trial that the company must conduct after approval,” she said.

DMD is a genetic disorder that causes the muscles to weaken and degenerate over time. Symptoms can appear as early as three years of age. It often affects boys, although there are rare cases of girls with DMD.

As the child grows, the muscles continue to weaken until the child can no longer perform normal activities. Upon reaching 12 or early teens, the patient will begin to require a wheelchair. Eventually, heart and respiratory muscles also start to weaken. Patients often die early, surviving up to their 20s or 30s.

One out of 3,600 infants worldwide have DMD.

Murdoch University researcher Steve Wilton, one of the drug developers, said the drug allowed patients to walk “past their loss of ambulation date.”

"These sick kids were on the edge of a cliff, they were about the lose the ability to walk,” he remarked.

With the recent approval of Exondys 51, many families whose lives have been affected by the disease could not help but feel a surge of hope. Fiona and Rob Ball, parents of six-year-old Maddox, are among them.

On the outside, Maddox appears to be functioning normally like other kids, but his movements are already showing telltale signs of the disease. For instance, he displays a slight limp when he runs. Because of this, he cannot run as fast as the other kids.

Maddox would jokingly say he has “naughty muscles.”

"He calls them naughty muscles and he just finds it hard to keep up with everybody else," Fiona said.

Although Exondys 51 does not cover Maddox’s genetic mutation, Fiona is hopeful that it would open up new possibilities for DMD treatment.

"It would completely change our whole lives and change Maddox's life," she said.

    Most Popular
  • Is 'The Last Supper' worth watching? Audience and critics weigh in

    Is 'The Last Supper' worth watching? Audience and critics weigh in

    Faith-based films often receive mixed reactions, and The Last Supper is no exception. The movie attempts to bring a fresh perspective to one of the most iconic moments in Christian history, but does it succeed? Some reviews from critics and audiences provide insight into its strengths and shortcomings.

  • ‘The Chosen’ Season 5: The darkest season yet—What to know before watching

    The wait is over—The Chosen is back with its fifth season, and this time, things are getting intense. The new episodes dive straight into the final days of Jesus’ life, covering some of the most emotional and dramatic moments in the Bible. If you’ve been following the series, you already know that The Chosen isn’t just about retelling familiar stories—it’s about bringing them to life in a way that feels real.

  • Massacres in Syria: Over 1,000 dead, including Christians and Alawites

    Syria’s coastal regions have been devastated by a series of massacres, with reports indicating that over 1,000 people—many from Christian and Alawite communities—have been killed in brutal attacks. Entire families have been wiped out, and survivors are fleeing in search of safety as sectarian violence escalates.

  • Kim Sae-ron and Wheesung: The tragic irony of Korean society and the principles of happiness

    Not long ago, the media was in an uproar over actress Kim Sae-ron’s passing. Just months before, the same people who had relentlessly criticized her for her DUI incident were now expressing sympathy, saying, "The world was too harsh on her." The irony is impossible to ignore.

  • Newsboys move forward as a quartet after Michael Tait’s departure

    After more than a decade as the lead singer of the Newsboys, Michael Tait has officially parted ways with the band, marking a significant shift in the Christian rock group’s lineup. The remaining members—Jeff Frankenstein, Jody Davis, Duncan Phillips, and Adam Agee—have assured fans that they will continue forward, embracing a new season of music and ministry.